BioCentury
ARTICLE | Company News

GlaxoSmithKline, Codexis deal

July 28, 2014 7:00 AM UTC

Codexis granted GlaxoSmithKline a non-exclusive, worldwide license to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing existing GSK drugs. Under the license, GSK can also use the technology to develop new drugs and diagnostics. Codexis will receive $6 million up front and an additional $19 million in technology transfer milestones expected to occur in the next two years. Codexis is also eligible for milestone payments ranging from $5.8-$38.5 million per project, plus low single-digit royalties. CodeEvolver uses directed evolution technology to determine which gene and enzyme mutations are beneficial or detrimental to manufacturing processes. ...